Literature DB >> 22987947

How to approach patients in relapse.

E Pujade-Lauraine1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22987947     DOI： 10.1093/annonc/mds358

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer.

Authors:  Yan Zhang; Qian Mei; Yang Liu; Xiang Li; Malcolm V Brock; Meixia Chen; Liang Dong; Lu Shi; Yao Wang; Mingzhou Guo; Jing Nie; Weidong Han
Journal:  Oncoimmunology       Date:  2017-05-17       Impact factor: 8.110

2.  Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995-2008.

Authors:  Jenny J Lin; Natalia Egorova; Rebeca Franco; Monica Prasad-Hayes; Nina A Bickell
Journal:  Obstet Gynecol       Date:  2016-01       Impact factor: 7.661

3.  Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.

Authors:  Miriam Champer; Yongmei Huang; June Y Hou; Ana I Tergas; William M Burke; Grace Clarke Hillyer; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2017-11-16       Impact factor: 5.482

Review 4.  Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.

Authors:  José Antonio López-Guerrero; Ignacio Romero; Andrés Poveda
Journal:  Chin J Cancer       Date:  2015-01

5.  Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.

Authors:  María Jesús Rubio Pérez
Journal:  Case Rep Oncol       Date:  2017-05-09

6.  Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Haihong Wang; Tie Xu; Lifen Zheng; Guiling Li
Journal:  Int J Gynecol Cancer       Date:  2018-06       Impact factor: 3.437

7.  Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer.

Authors:  Eva María Guerra Alía; Cayetano Sempere Ortega; Alfonso Cortés Salgado; Concepción Sanchez Martínez; Julio Galindo Álvarez; Belén Pérez Miez
Journal:  Case Rep Oncol       Date:  2019-06-13

8.  Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures.

Authors:  Kun-Hsing Yu; Douglas A Levine; Hui Zhang; Daniel W Chan; Zhen Zhang; Michael Snyder
Journal:  J Proteome Res       Date:  2016-07-08       Impact factor: 4.466

Review 9.  Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

Authors:  Floriana Mascilini; Giulia Amadio; Maria Grazia Di Stefano; Manuela Ludovisi; Alessia Di Legge; Carmine Conte; Rosa De Vincenzo; Caterina Ricci; Valeria Masciullo; Vanda Salutari; Giovanni Scambia; Gabriella Ferrandina
Journal:  Onco Targets Ther       Date:  2014-07-12       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.